Currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the Child Pugh classification)
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
CRITERIA SPECIFIC FOR COHORT #2 (MCL): Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification.
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class A, B or C according to the Child Pugh classification
Hepatic impairment:\r\n* Phase I: any currently active, clinically significant hepatic impairment (Child-Pugh class A, B, or C according to the Child Pugh classification)\r\n* Phase II: currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Subjects with chronic liver disease with hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child-Pugh classification
Currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the NCI/Child Pugh classification)
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Subjects with currently active, clinically significant hepatic impairment (> moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification)
Patient must not have currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the NCI/Child Pugh)
Currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification
Currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification)
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Currently active, clinically significant hepatic impairment (? moderate hepatic impairment according to the Child Pugh classification).
Currently active, clinically significant hepatic impairment >= moderate hepatic impairment according to the National Cancer Institute (NCI)/Child Pugh classification
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically significant hepatic impairment (Child-Pugh class B or C)